Literature DB >> 25912550

Cryptotanshinone, a Stat3 inhibitor, suppresses colorectal cancer proliferation and growth in vitro.

Weidong Li1, Shakir M Saud, Matthew R Young, Nancy H Colburn, Baojin Hua.   

Abstract

Cryptotanshinone (CPT) is a natural compound extracted from herbal medicine that has been previously shown to possess antitumor properties in various types of human cancer cells. In the present study, we examined the potential role of CPT in the treatment of colorectal cancer. Using SW480, HCT116, and LOVO colorectal cancer cell lines, the effects of CPT on cell viability, apoptosis, and tumorigenicity were evaluated. The results showed that CPT significantly inhibited the growth and viability of SW480, HCT116, and LOVO cell lines by inducing apoptosis and prevented anchorage dependent growth on agar. In addition, CPT inhibited the activation of Signal transducer and activator of transcription 3 (Stat3) pathways in colorectal cancer cells. Stat3 is a transcription factor that mediates the expression of various genes associated with many cellular processes, such as inflammation and cell growth, and has been shown to promote several cancer types, including colorectal cancer. These findings indicate that CPT may be a potential candidate for the treatment and prevention of colorectal cancer in part by inhibiting the activation of Stat3.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25912550     DOI: 10.1007/s11010-015-2424-0

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  57 in total

1.  STAT3 implicated in the development of colon cancer: a step closer for targeted therapy?

Authors:  George K K Lau; Dewei Ye
Journal:  Gastroenterology       Date:  2010-07       Impact factor: 22.682

2.  [Effect of JAK2/STAT3/vimentin signaling pathway on proliferation and migration of human colon cancer cells].

Authors:  Jian-hua Xu; Chao Zhang; Bo Tang; Ying-xue Hao; Jun Chen; Tao Liu; Hao Cui
Journal:  Zhonghua Wei Chang Wai Ke Za Zhi       Date:  2010-04

3.  Cryptotanshinone inhibits lung tumorigenesis and induces apoptosis in cancer cells in vitro and in vivo.

Authors:  Liang Chen; Hui-Juan Wang; Wenli Xie; Yunyi Yao; Yan-Shan Zhang; Huiling Wang
Journal:  Mol Med Rep       Date:  2014-03-31       Impact factor: 2.952

4.  Simultaneous determination of danshensu, rosmarinic acid, cryptotanshinone, tanshinone IIA, tanshinone I and dihydrotanshinone I by liquid chromatographic-mass spectrometry and the application to pharmacokinetics in rats.

Authors:  Yun Liu; Xiaorong Li; Yuhang Li; Lijuan Wang; Ming Xue
Journal:  J Pharm Biomed Anal       Date:  2010-04-08       Impact factor: 3.935

5.  Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells.

Authors:  R Garcia; T L Bowman; G Niu; H Yu; S Minton; C A Muro-Cacho; C E Cox; R Falcone; R Fairclough; S Parsons; A Laudano; A Gazit; A Levitzki; A Kraker; R Jove
Journal:  Oncogene       Date:  2001-05-03       Impact factor: 9.867

6.  Cryptotanshinone activates p38/JNK and inhibits Erk1/2 leading to caspase-independent cell death in tumor cells.

Authors:  Wenxing Chen; Lei Liu; Yan Luo; Yoshinobu Odaka; Sanket Awate; Hongyu Zhou; Tao Shen; Shizhong Zheng; Yin Lu; Shile Huang
Journal:  Cancer Prev Res (Phila)       Date:  2012-04-03

Review 7.  Survivin, cancer networks and pathway-directed drug discovery.

Authors:  Dario C Altieri
Journal:  Nat Rev Cancer       Date:  2008-01       Impact factor: 60.716

8.  Protective effect of cryptotanshinone on lipopolysaccharide-induced acute lung injury in mice.

Authors:  Ying Tang; Yulong Chen; Zhe Chu; Bo Yan; Lijun Xu
Journal:  Eur J Pharmacol       Date:  2013-10-24       Impact factor: 4.432

9.  Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma.

Authors:  Yoshiyasu Aoki; Gerald M Feldman; Giovanna Tosato
Journal:  Blood       Date:  2002-10-03       Impact factor: 22.113

10.  BM-1197: a novel and specific Bcl-2/Bcl-xL inhibitor inducing complete and long-lasting tumor regression in vivo.

Authors:  Longchuan Bai; Jianfang Chen; Donna McEachern; Liu Liu; Haibin Zhou; Angelo Aguilar; Shaomeng Wang
Journal:  PLoS One       Date:  2014-06-05       Impact factor: 3.240

View more
  22 in total

1.  US National Cancer Institute-China Collaborative Studies on Chinese Medicine and Cancer.

Authors:  Libin Jia; Hongsheng Lin; Joost Oppenheim; O M Zack Howard; Jie Li; Huiting Fan; Zhizheng Zhao; William Farrar; Ying Zhang; Nancy Colburn; Matthew R Young; Weidong Li; David Newman; Barry R O'Keefe; John Beutler; Jikai Liu; Xiaojiang Hao; Xiaosheng Yang; Tengfei Ji; Jeffrey D White
Journal:  J Natl Cancer Inst Monogr       Date:  2017-11-01

2.  TWEAK protects cardiomyocyte against apoptosis in a PI3K/AKT pathway dependent manner.

Authors:  Bin Yang; Ping Yan; Hui Gong; Lin Zuo; Ying Shi; Jian Guo; Rui Guo; Jun Xie; Bao Li
Journal:  Am J Transl Res       Date:  2016-09-15       Impact factor: 4.060

3.  Novel STAT3 Inhibitors Targeting STAT3 Dimerization by Binding to the STAT3 SH2 Domain.

Authors:  Yaping Hua; Xing Yuan; Yun-Heng Shen; Jinxin Wang; Waqas Azeem; Shuo Yang; Alexandra Gade; Seyed Mohammad Lellahi; Anne Margrete Øyan; Xisong Ke; Wei-Dong Zhang; Karl-Henning Kalland
Journal:  Front Pharmacol       Date:  2022-05-27       Impact factor: 5.988

4.  Chk1 Inhibition Potently Blocks STAT3 Tyrosine705 Phosphorylation, DNA-Binding Activity, and Activation of Downstream Targets in Human Multiple Myeloma Cells.

Authors:  Liang Zhou; Xinyan Pei; Yu Zhang; Yanxia Ning; Lin Li; Xiaoyan Hu; Sri Lakshmi Chalasani; Kanika Sharma; Jewel Nkwocha; Jonathan Yu; Dipankar Bandyopadhyay; Said M Sebti; Steven Grant
Journal:  Mol Cancer Res       Date:  2022-03-01       Impact factor: 6.333

Review 5.  Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution.

Authors:  Uddalak Bharadwaj; Moses M Kasembeli; Prema Robinson; David J Tweardy
Journal:  Pharmacol Rev       Date:  2020-04       Impact factor: 25.468

6.  Perspectives on the Clinical Development of NRF2-Targeting Drugs.

Authors:  Diego Lastra; Raquel Fernández-Ginés; Gina Manda; Antonio Cuadrado
Journal:  Handb Exp Pharmacol       Date:  2021

7.  Cryptotanshinone inhibits human glioma cell proliferation in vitro and in vivo through SHP-2-dependent inhibition of STAT3 activation.

Authors:  Liang Lu; Sulin Zhang; Cuixian Li; Chun Zhou; Dong Li; Peiqing Liu; Min Huang; Xiaoyan Shen
Journal:  Cell Death Dis       Date:  2017-05-11       Impact factor: 8.469

8.  Cryptotanshinone potentiates the antitumor effects of doxorubicin on gastric cancer cells via inhibition of STAT3 activity.

Authors:  Jiye Wang; Guangji Zhang; Chunyan Dai; Xiufei Gao; Jianbin Wu; Li Shen; Zhe Chen; Pei Liu
Journal:  J Int Med Res       Date:  2017-01-25       Impact factor: 1.671

9.  Cryptotanshinone inhibits proliferation yet induces apoptosis by suppressing STAT3 signals in renal cell carcinoma.

Authors:  Zhiguo Chen; Rujian Zhu; Jiayi Zheng; Chen Chen; Chi Huang; Junjie Ma; Chen Xu; Wei Zhai; Junhua Zheng
Journal:  Oncotarget       Date:  2017-07-25

10.  Cryptotanshinone induces cell cycle arrest and apoptosis through the JAK2/STAT3 and PI3K/Akt/NFκB pathways in cholangiocarcinoma cells.

Authors:  Fayong Ke; Zheng Wang; Xiaoling Song; Qiang Ma; Yunping Hu; Lin Jiang; Yijian Zhang; Yingbin Liu; Yong Zhang; Wei Gong
Journal:  Drug Des Devel Ther       Date:  2017-06-15       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.